The t(8;21) chromosomal translocation that generates the fusion oncoprotein RUNX1-ETO predominates in leukemia patients of the French-American-British (FAB) class M2 subtype. The oncoprotein has the capacity to promote expansion of hematopoietic stem/progenitor cells and induces leukemia in association with other genetic alterations. Here, we show that RUNX1-ETO undergoes degradation in response to treatment with histone deacetylase inhibitors, one of which, depsipeptide (DEP), is currently undergoing phase II clinical testing in a variety of malignancies. These compounds induce turnover of RUNX1-ETO without affecting the stability of RUNX1-ETO partner proteins. In addition, RUNX1-ETO physically interacts with heat shock protein 90 (HSP90). DEP treatment interrupts the association of RUNX1-ETO with HSP90 and induces proteasomal degradation of RUNX1-ETO. DEP and the HSP90 antagonist 17-allylamino-geldanamycin (17-AAG) both triggered RUNX1-ETO degradation, but without any additive or cooperative effects. These findings may stimulate the development of more rational and effective approaches for treating t(8;21) patients using histone deacetylase inhibitors or HSP90 inhibitors.
Introduction
The t(8;21) is one of the most frequent chromosomal translocations associated with acute myeloid leukemia (AML). It is characteristic of the M2 subtype of AML (French-American-British classification system), as nearly 45% of these leukemias harbor the t(8;21). This translocation creates a chimeric gene that encodes a fusion protein containing the N-terminal DNA binding domain of the RUNX1 (Runt-related X1, also known as AML1) transcription factor fused to nearly all of the transcriptional corepressor ETO (eight-twenty-one, also known as MTG8 or Myeloid Translocation Gene on chromosome 8). Therefore, the fusion protein retains the ability to bind to DNA via RUNX1 DNA recognition motifs and to repress genes that are normally regulated by RUNX1 (Linggi et al., 2005) .
RUNX1-ETO acts to repress the transcription of key regulatory genes, including transcription factors that regulate cell cycle control and myeloid differentiation such as C/EBPa (Pabst et al., 2001) . In addition, the fusion protein represses the p14 ARF and NF1 tumor suppressors (Linggi et al., 2002; Yang et al., 2005) . Mechanistically, the fusion protein represses transcription by recruiting mSin3A and mSin3B, the nuclear hormone corepressors N-CoR and SMRT, as well as directly associating with histone deacetylases (HDAC) 1, 2 and 3 (Gelmetti et al., 1998; Lutterbach et al., 1998; Wang et al., 1998; Amann et al., 2001; Hildebrand et al., 2001) . Given that the mSin3 corepressors themselves associate with HDAC1 and HDAC2, while N-CoR and SMRT bind to HDAC3, it is likely that the action of HDACs play a key role in RUNX1-ETO-mediated repression (Amann et al., 2001) . Indeed, histone deacetylase inhibitors (HDIs) impair RUNX1-ETOmediated repression, and histone deacetylase activity is associated with the fusion protein (Lutterbach et al., 1998) .
The HDACs are enzymes that catalyse the removal of acetate from lysine residues in the N-terminal tails of histones. These modifications regulate chromatin structure, which affects gene expression, DNA synthesis, mitosis and ultimately cell proliferation and survival (Hake et al., 2004; Drummond et al., 2005) . In addition to acetylation, lysine residues within the histone tails can also be modified by methylation, ubiquitylation and sumoylation in comprising a 'histone code' (Jenuwein and Allis, 2001; Hake et al., 2004; Linggi et al., 2005) . That is, a particular modification in turn affects subsequent modifications; thus, the alteration of a single type of histone modification can trigger changes in other 'marks', leading to alterations in gene expression (Hake et al., 2004) . Moreover, 'trans' histone regulation of chromatin also occurs, as exemplified by histone H2B ubiquitylation regulating histone H3 Lys 4 methylation (Sun and Allis, 2002) .
In addition to the acetylation of histones, nonhistone proteins are also targeted by histone acetyltransferases and HDACs to regulate the action of these factors. For example, p300-mediated acetylation of the RUNX1-related factor RUNX3 blocks ubiquitylation at those lysine residues and hence stabilizes the protein (Jin et al., 2004) . In addition to protein stability, the acetylation of other proteins can regulate their activity. For example, acetylation of the BCL6 transcription factor impairs its ability to bind to DNA (Bereshchenko et al., 2002) , and acetylation of HSP90 impairs its ability to aid in the folding of client proteins (Fuino et al., 2003; Aoyagi and Archer, 2005; Bali et al., 2005; Kovacs et al., 2005) . Therefore, the protein acetylation state, set by competing histone acetyltransferase and HDAC activities, represents a key regulatory node.
Certain histone deacetylase inhibitors were initially discovered through their ability to induce the differentiation of leukemia cell lines (Marks et al., 2004) . Subsequent studies found that these agents not only induce the differentiation of a wide range of cell types, but also inhibit cell cycle progression, and induce cell death in a wide range of tumor-derived cell lines (Hake et al., 2004; Drummond et al., 2005) . However, the molecular basis for their anticancer selectivity remains largely unknown, with the possibilities ranging from the transcriptional activation of cyclin-dependent kinase inhibitors to the triggering of mitotic catastrophe due to an inability to condense chromosomes (Johnstone and Licht, 2003; Linggi et al., 2005) . Phase II studies of the HDI depsipeptide (DEP, also known as FK228 and FR901228), alone or in combination with other anticancer agents, are ongoing to determine the clinical efficacy of this compound in solid and hematological tumors (Piekarz and Bates, 2004) . Preliminary results of these clinical trials indicate that DEP is well tolerated and exhibits significant clinical activity against cutaneous T-cell lymphoma (Pichardo et al., 2004; .
For acute leukemias, the tight association of a given chromosomal translocation with a specific subtype of leukemia implies that the altered gene at the translocation breakpoint is the initiating event. Therefore, therapeutic approaches that directly target the t(8;21) chromosomal translocation fusion protein would likely be as effective as targeted therapeutics that have been identified for BCR-ABL or PML-RARa associated leukemia (Huang et al., 1988; Druker et al., 1996; Chen et al., 1997; Druker, 2002) . For PML-RARa, all-trans retinoic acid not only inactivates the fusion protein, but causes its destruction (Raelson et al., 1996; Yoshida et al., 1996; Zhu et al., 1997; Muller et al., 1998; Shao et al., 1998) . For those chromosomal translocation fusion proteins such as RUNX1-ETO for which a clear small molecule approach is not evident, attacking the histone deacetylases, which the fusion protein recruits to repress transcription, is a rational, albeit indirect approach. Here, we show that HDIs, in addition to affecting histone acetylation levels, trigger the degradation of the t(8;21) fusion protein, opening the possibility that HDIs may provide an unexpected therapeutic benefit for patients with the t(8;21).
Results
Histone deacetylase inhibitors induce turnover of RUNX1-ETO RUNX1-ETO represses the transcription of a subset of RUNX1-regulated genes by recruiting histone deacetylases (HDACs) and other transcriptional corepressors to target promoters (Linggi et al., 2005) . The HDI Trichostatin A (TSA) alleviates RUNX1-ETO-mediated repression in transcription reporter assays (Lutterbach et al., 1998) . While investigating the effects of TSA on Kasumi-1 leukemic cells that contain a t(8;21), we found that the levels of the fusion protein were greatly reduced after addition of TSA to the culture medium. Densitometry analysis of the Western blot indicated that the levels of RUNX1-ETO protein were reduced eightfold within 16-24 h of TSA treatment and this effect was dose and time dependent (Figure 1a and b) . The reduction in the levels of the fusion protein occurred before obvious signs of cell death (as judged by Trypan blue exclusion assays), suggesting the increased turnover specifically resulted from TSA treatment. The RUNX1-ETO protein was essentially eliminated after de novo protein synthesis was blocked by cyclohexamide (CHX) treatment for 4-6 h following 10 h of TSA administration (Figure 1c ), indicating that TSA decreased the halflife of RUNX1-ETO.
Although TSA is a potent HDI in vitro, pharmacokinetic studies indicate that it is rapidly inactivated in vivo (Vanhaecke et al., 2004) , which adversely affects its bioavailability and antitumor activity. By contrast, DEP is a natural tetrapeptide HDAC inhibitor that is currently in phase I and II clinical trials for treating hematological malignancies and solid tumors (Piekarz et al., 2001; Marshall et al., 2002; Sandor et al., 2002; Piekarz and Bates, 2004; Byrd et al., 2005) . DEP inhibits all the known Class I and Class II HDAC enzymes (Nakajima et al., 1998) . DEP is typically used at a concentration of 5 nM, but even at 10-fold lower levels it caused a dramatic accumulation of acetylated histones (Figure 2a and b) . At higher doses of DEP (5.0 nM), the degradation of RUNX1-ETO was quite rapid, with most of the protein being degraded by 8 h post drug addition (Figure 2c) . However, by 12 h a high percentage of cells were bound by APC-conjugated Annexin V, which is indicative of apoptosis (data not shown) and this prevented further analysis of these cells. Nevertheless, even at these comparatively high levels of DEP, degradation of RUNX1-ETO appeared to be dependent on proteasomal function, as MG132 completely blocked RUNX1-ETO turnover (Figure 2d ). DEP triggers cell cycle arrest and subsequent cellular differentiation or apoptosis in various cell systems (Sandor et al., 2000; Sato et al., 2004; Tabe et al., 2005) . As 5 nM DEP induced apoptosis within 12 h, we were unable to determine the effects of this compound on cell cycle arrest and subsequent cellular differentiation. Given that DEP-induced histone acetylation at 0.5 nM, we further reduced the concentration of DEP to only 5.0 pM and assessed the effects on histone acetylation and RUNX1-ETO levels. At this low level of DEP, histone acetylation once again accumulated by 8 h and the levels of the fusion protein began to decrease between 4 and 8 h (Figure 3a ). Therefore, we tested the effects of 5 pM DEP on myeloid differentiation and cell cycle progression of Kasumi-1 cells. No cell surface expression of CD11b was observed within 16 h of drug addition, but it was expressed at later time points, indicating that the loss of RUNX1-ETO was not due to differentiation. Likewise, within 12-16 h we did not observe overt alterations in the cell cycle profile of Kasumi-1 cells treated with DEP and analysed using propidium iodide (PI) staining for DNA content and flow cytometry analysis (Figure 3c 
RUNX1-ETO degradation in response to HDIs
G Yang et al fusion protein we used the caspase inhibitor Z-VAD to block apoptosis induced by DEP. For this analysis we used 2 nM of drug, which triggered apoptosis more rapidly and 18% of the cells were Annexin V positive by 10 h (Figure 4a ). Addition of 50 mM Z-VAD to the culture medium was sufficient to block DEP-induced apoptosis (Figure 4a ). When cell lysates made from these same cultures were assessed for expression of the fusion protein, we found that RUNX1-ETO levels were reduced in both the absence and presence of Z-VAD, which confirms that the destabilization is not secondary to the induction of apoptosis (Figure 4b ). Anticancer drugs trigger cellular stress reactions, which may lead to nonspecific degradation of cellular proteins. To test whether HDIs act simply by inducing cellular stress, Kasumi-1 cells were treated with HDIs (DEP and TSA) and other commonly used antineoplastics (doxorubicin (DOXO), cytarabine and etopside). To make the results comparable, the concentration of each drug was titrated to yield a similar amount of apoptosis in PI staining and flow cytometry analysis (data not shown). DEP and TSA induced the turnover of RUNX1-ETO most effectively, as the other anticancer reagents failed to dramatically reduce the protein levels ( Figure 5a ). The one possible exception was etoposide, which caused a modest reduction in RUNX1-ETO levels under the conditions used in Figure 5a , but caused a more dramatic reduction in the levels of the fusion protein at higher concentrations (data not shown).
As chromosomal translocations affect only one allele, using anti-RUNX1 we detected a band that migrated with a molecular weight consistent with that of the wildtype RUNX1, which was also reduced by treatment with TSA and DEP (Figure 5a ). However, this interpretation is complicated by the variety of truncated forms of RUNX1-ETO in Kasumi-1 cells, some of which are predicted to migrate only 5 kDa slower than RUNX1 (Yan et al., 2004 ). Therefore, we tested whether wildtype RUNX1 or ETO might also be sensitive to degradation in response to HDIs in human erythroleukemia (HEL) cells, which express easily detectable levels of RUNX1 and ETO. RUNX1 levels were reduced in response to both DEP and TSA treatment and were affected to some degree by etoposide, but were not affected by the other anticancer drugs (Figure 5b) . Likewise, ETO levels were reduced after TSA and DEP administration, with a more modest response to etoposide, but little or no response to DOXO or cytarabine (Figure 5b ). Thus, induction of cellular stress may be one component underlying the induction of RUNX1-ETO degradation, but HDIs appear to more actively induce degradation than the other compounds.
17-AAG triggers the loss of RUNX1-ETO
The destabilization of RUNX1-ETO could be due to the accumulation of acetylation of either the fusion protein itself, acetylation of proteins that associate with the fusion protein, or by acetylation of factors that regulate the folding and/or turnover of RUNX1 or ETO. Although RUNX1 and RUNX3 are acetylated, this modification appears to stabilize the factor rather than cause its degradation (Jin et al., 2004; Yamaguchi et al., 2004) . In addition, we were unable to detect the fusion protein using anti-acetyl-lysine after HDI treatment (data not shown). Therefore, we tested whether the modification of associated proteins or the inhibition of the enzymatic activity of HDACs might cause the RUNX1-ETO repression complex to fall apart, exposing the fusion protein to the degradation machinery. HDAC3 was readily detectable in Kasumi-1 cells, and immunoprecipitation of RUNX1-ETO followed by Western blot analysis indicated that HDAC3 was still detected 4 h after DEP addition to the culture medium ( Figure 6 ). Although the amount of associated HDAC3 was somewhat reduced in the HDI-treated cells, this reduction was consistent with the reduced level of the fusion protein at this early time (Figure 6 ), indicating that inhibition of HDAC3 did not affect its interaction with RUNX1-ETO. Next, we tested whether alterations of chaperones for the fusion protein might alter its stability. HSP90 is acetylated and HDI treatment results in the accumulation of acetylated HSP90 and the degradation of the HSP90 client protein AKT (Fuino et al., 2003; Aoyagi and Archer, 2005; Bali et al., 2005; Kovacs et al., 2005) . Given that ETO interacts with HSP90 (Komori et al., 1999) and that ETO also undergoes degradation in response to DEP treatment (Figure 5b ), we tested whether inhibitors of HSP90 might also affect the levels of RUNX1-ETO. The folding and thus stabilization of client proteins by HSP90 is dependent on binding and hydrolysis of ATP at the N-terminus of HSP90. 17-allylamino-geldanamycin (17-AAG) is an antagonist of HSP90 that works by competing with ATP for binding to HSP90 (Prodromou and Pearl, 2003) . As shown in Figure 7a , 17-AAG increased RUNX1-ETO turnover in Kasumi-1 cells in a dose-and timedependent manner. The protein levels dropped between 2-and 4-fold after treatment with 1.0 mM 17-AAG for 8 and 24 h, respectively (Figure 7a ). 1.0 mM 17-AAG treatment reduced RUNX1-ETO protein levels by about 50% within 8 h (Figure 7a ). The effects appeared to be specific since 17-AAG did not change the levels of mSin3B protein (Figure 7a ). In contrast, p21 CIP1/WAF1 expression was induced as previously reported Figure 5 Chemotherapeutic drugs do not induce RUNX1-ETO turnover. (a) Kasumi-1 cells were cultured for 12 h without (DMSO only as a control), or with 5.0 nM DEP, 2.0 mM TSA, 0.5 mg/ml DOXO, 100 mg/ml cytarabine (CYTA.), or 5.0 mg/ml etoposide (ETOP.). Western blot analysis was performed using anti-RUNX1-N that recognizes both RUNX1-ETO and RUNX1 and anti-GAPDH as a loading control. Overexpressed RUNX1-ETO and RUNX1 were used as positive controls to mark the positions of these proteins. (b) RUNX1 and ETO are also sensitive to HDIs. HEL cells were subjected to the same treatment and Western blot analysis was performed as described in (a). Overexpressed RUNX1 protein was used as a positive control. 
cells was immunoprecipitated using anti-RUNX1-N and detected by Western blot using anti-RUNX1 RHD (upper panel). The copurified HDAC3 was detected using Western blot analysis (middle panel). Western blot analysis of the whole-cell lysate indicated that HDAC3 levels remain unchanged after DEP treatment (lower panel).
RUNX1-ETO degradation in response to HDIs G Yang et al (Figure 7a , (George et al., 2005) ). In addition, we reasoned that if DEP and 17-AAG act via distinct pathways, then combining these compounds might cooperate in accelerating the destruction of RUNX1-ETO. Therefore, we treated Kasumi-1 cells with a combination of 1.0 mM 17-AAG and 0.5 nM DEP (Figure 7b ). Coadministration of DEP with 17-AAG did not have either synergistic or additive effects on RUNX1-ETO levels in Kasumi-1 cells (Figure 7b ). These data are consistent with the possibility that both of these compounds act on the same biochemical pathway.
Given that DEP did not cooperate with 17-AAG in inducing RUNX1-ETO turnover (Figure 7b) , we hypothesized that DEP and 17-AAG act on the same regulatory node, that is, HSP90, to stimulate the degradation of its client protein, RUNX1-ETO. Therefore, we tested whether the fusion protein associates with HSP90 and, if so, if DEP could trigger the release of RUNX1-ETO from HSP90, which would facilitate its degradation as an unfolded or partially folded protein. Indeed, we found that HSP90 co-immunoprecipitated with RUNX1-ETO from Kasumi-1 cells using either anti-HSP90 to precipitate RUNX1 or anti-RUNX1 to precipitate HSP90 (Figure 7c and d) . This interaction was diminished in response to DEP treatment (Figure 7d ), even at early times after the addition of DEP when minimal decreases in RUNX1-ETO were detected.
Finally, we wished to extend these results to primary leukemia samples containing the t(8;21). Bone marrow samples were cocultured with HS5 cells as a feeder layer (Garrido et al., 2001) , which maintained the viability of the leukemic cells for several days (data not shown). Although Kasumi-1 cells are very sensitive to DEP, these leukemic blasts were much less susceptible to even 5.0 nM DEP, showing no decrease in viability up to 16 h after drug treatment (as judged by Trypan blue exclusion, data not shown). This is likely due to the survival signals provided by the HS5 cells. Nevertheless, 16 h after DEP addition the levels of the t(8;21) fusion protein were markedly reduced (Figure 8 ). By contrast, the levels of acetylated histone H3 and H4 increased and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression remained approximately equal. Thus, DEP may be effective at reducing the expression of the fusion protein in primary AML samples.
Discussion
The tight association of the t(8;21) with the FAB M2 subtype of AML suggests that the production of the RUNX1-ETO fusion protein plays a critical role in this leukemia. That the t(8;21) can be an initiating event in leukemia was demonstrated in numerous mouse models that indicate that expression of the fusion protein can set the stage for the formation of AML. Mice with targeted expression of RUNX1-ETO show an increased capacity for hematopoietic stem cell self-renewal and immortalization in vitro, and when the fusion protein was expressed in Sca1 þ cells, the mice developed a spontaneous myeloproliferative disorder (Okuda et al., 1998;  Western blot was performed using anti-RUNX1-RHD and antimSin3B antibodies as a control. (c) RUNX1-ETO associates with HSP90. Kasumi-1 cell lysates were immunoprecipitated with normal rabbit IgG (NRI), or anti-HSP90, followed by Western blot analysis using anti-RUNX1-N. (d) DEP causes release of RUNX1-ETO from HSP90. Kasumi-1 cells were cultured for 4 h in the presence of 0.5 nM DEP or DMSO as a control. The lysates were immunoprecipitated with normal rabbit IgG (NRI), or 5 mg anti-RUNX1-N, followed by Western blot analysis using anti-RUNX1-RHD or anti-HSP90 antibody. The input control indicated that DEP treatment (0.5 nM for 4 h) did not alter HSP90 levels and only modestly affected RUNX1-ETO levels. , 2004) . RUNX1-ETO expression in conjunction with treatment with the mutagen N-ethyl-N-nitrosourea (ENU) resulted in myeloid leukemia or granulocytic sarcoma (Yuan et al., 2001; Higuchi et al., 2002) . Therefore, RUNX1-ETO is able to predispose myeloid precursors to transformation. As such, the fusion protein is an ideal target for the development of novel therapeutic strategies that seek to impair the action of this chimeric transcription factor. The first such targeted therapy for a chimeric transcription factor was all-trans retinoic acid (ATRA) for the treatment of acute promyelocytic leukemia. ATRA binds to the retinoic acid receptor portion of the t(15;17) fusion protein and induces both the release of transcriptional corepressors and the eventual degradation of the fusion protein (Raelson et al., 1996; Yoshida et al., 1996; Zhu et al., 1997; Muller et al., 1998; Shao et al., 1998) . Likewise, arsenic trioxide is effective in the treatment of APL, because it triggers the destruction of PML-RARa Muller et al., 1998; Shao et al., 1998) . Here, we demonstrate that HDIs induce the turnover of the myeloid oncoprotein RUNX1-ETO in Kasumi-1 cells.
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The degradation of RUNX1-ETO that is triggered by HDIs is likely due to hyperacetylation of proteins other than the fusion protein, as we were unable to detect the fusion protein using anti-acetyl-lysine antibodies (data not shown). RUNX family members such as RUNX3 can be acetylated, but rather than this acetylation triggering its destruction, acetylation of RUNX3 blocks ubiquitin-mediated degradation (Jin et al., 2004) . Thus, the effects of HDIs on RUNX1-ETO and RUNX1 are opposite to the expected results if the effect is direct. By contrast, anti-acetyl-lysine was used to demonstrate that acetylated HSP90 accumulates in myeloid cells after HDI treatment in myeloid cell lines (Fuino et al., 2003; Aoyagi and Archer, 2005; Bali et al., 2005; Kovacs et al., 2005) . HSP90 may play a pivotal role in the folding of translocation fusion proteins, as these chimeras are likely to have difficulty folding on their own accord. Indeed, RUNX1-ETO physically associates with HSP90 (Figure 7c and d) and the interaction is interrupted by DEP treatment (Figure 7d ). In addition, DEP and 17-AAG did not cooperate in stimulating the degradation of the fusion protein (Figure 7b ), suggesting that these compounds act in the same pathway. However, 17-AAG did trigger the degradation of RUNX1-ETO when tested as a single agent (Figure 7a ). Thus, both HDIs and HSP90 inhibitors might be efficacious in t(8;21) AML.
Although HDIs cause activation of numerous genes, it is also notable that we did not observe a dramatic induction of the mRNA encoding the p21 cyclindependent kinase inhibitor, using either DEP or TSA (data not shown), but 17-AAG did trigger expression of p21 (Figure 7) . Likewise, the chimeric t(8;21) mRNA was not induced, but was actually decreased even within 4 to 8 h after HDI addition (data not shown). This effect is counterintuitive as HDIs cause the accumulation of acetylation on histones, which is correlated with activation of gene expression. Therefore, further work will be required to understand the mechanistic basis for the reduction in mRNA levels. Nevertheless, the loss of the RUNX1-ETO mRNA provides a second mechanism by which these compounds cause the loss of RUNX1-ETO expression.
As a possible initiating event in disease pathogenesis, elimination of RUNX1-ETO could potentially be clinically beneficial to the t(8;21) patients. HDIs such as DEP and phenylbutyrate induce growth arrest, differentiation and apoptosis of RUNX1-ETO-positive Kasumi-1 cells (Figure 2 ; (Wang et al., 1999; Klisovic et al., 2003) ). It is unlikely that these effects are due solely to inducing the degradation of the fusion protein, as these compounds also trigger death receptormediated apoptosis (Insinga et al., 2005; Sutheesophon et al., 2005) and inhibit chromosomal condensation before mitosis Johnstone, 2002; Piekarz and Bates, 2004) . Indeed, siRNAmediated knockdown of RUNX1-ETO expression had only modest effects on the viability of Kasumi-1 cells over short periods of time, but allowed the cells to be forced to differentiate in response to various agents (Heidenreich et al., 2003; Kasashima et al., 2004) . Antiacetylated histone H3 K9 and antiacetylated histone H4 were used to assess histone acetylation. Anti-GAPDH was used as a loading control. Trypan blue dye exclusion was used to ensure that the cells were viable 16 h after DEP addition. Shown is a representative analysis of one of the two AML samples used, both of which yielded similar results.
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However, the knockdown was not complete and ribozyme-mediated targeting of the fusion protein, as well as antisense RNA, appeared to be more effective at inducing both cellular differentiation and eventually cell death (Sakakura et al., 1994; Matsushita et al., 1995; Kozu et al., 2000; Szyrach et al., 2001) . Thus, DEP may be a potent targeted therapy for t(8;21) AML as it targets multiple pathways, including reducing the levels of RUNX1-ETO. Analysis of inducible murine model systems for the oncogenes c-Myc and BCR-ABL confirmed that elimination of the initiating event in tumorigenesis is an extremely effective therapeutic strategy (Felsher and Bishop, 1999; Huettner et al., 2000) . This is likely because the secondary cooperating mutations are selected to support the primary lesion and are not sufficient to sustain the transformed cell. In the clinic, the use of targeted therapeutics, such as Gleevec for BCR-ABL-induced CML, have produced paradigmshifting advances in the treatment of cancer (Druker, 2002) . Although HDIs do not directly target the oncogenic lesions in either leukemia or solid tumors, some efficacy has already been documented, especially in cutaneous T-cell lymphoma (Piekarz et al., 2001; Pichardo et al., 2004) . For AML, a phase II clinical study of DEP is in progress and preliminary results showed that the drug induced a rapid disappearance of bone marrow blasts with concomitant recovery of nearnormal hematopoiesis in a small number of patients with RUNX1-related translocations, including the t(8;21) (Odenike et al., 2004) . In contrast, DEP exhibited only modest antileukemic activity in patients with normal or other cytogenetics (Odenike et al., 2004) . The selective therapeutic effects of DEP on t(8;21) patients may be partially due to the drug-induced degradation of RUNX1-ETO protein. Given that DEP was able to trigger RUNX1-ETO turnover at very low concentration (5.0 pM, Figure 3) , it is possible that a much lower dose of DEP could be applied to t(8;21) patients, possibly in combination with standard chemotherapeutic approaches, such that any side effects of DEP may be alleviated or eliminated and a more favorable clinical outcome in t(8;21) patients obtained.
Materials and methods
Cell culture and drug treatment Kasumi-1 and human erythroleukemia (HEL) cells were maintained in RPMI, containing 10% fetal bovine serum (FBS) (Mediatech Inc., Herndon, VA, USA), 50 U/ml penicillin, 50 mg/ml streptomycin and 2 mM L-glutamine (all from BioWhittaker/Cambrex Corp., East Rutherford, NJ, USA). To ensure normal cell metabolism and reduce cell stress, cells were split at a density of 3-5 Â 10 5 /ml the day before drug treatment. TSA (GR-309, BioMol Research Laboratories Inc., Plymouth Meeting, PA, USA) or DEP (prepared by Fujisawa Pharmaceutical and obtained through the Developmental Therapeutics Program, National Cancer Institute, NSC 630176, CAS 128517-07-7) was dissolved in dimethylsulfoxide (DMSO) and added to culture medium at the concentrations indicated in the figure legends. MG132
Coimmunoprecipitations and immunoblotting
Cells were harvested and sonicated in modified RIPA buffer (50 mM Tris-HCl, pH 7.4, 1% NP-40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM ethylenediamine-N, N, N 0 , N 0 -tetraacetic acid, 1 mg/ml leupeptin, 0.5 mM phenylmethylsulphonyl fluoride (PMSF) and 0.1 U/ml aprotinin, 1 mM Na 3 VO 4 , 1 mM NaF). After centrifugation, the supernatants were subjected to 10% sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) or 4-20% criterion gel electrophoresis (Bio-Rad Laborotaries, Hercules, CA, USA) and blotted to polyvinyl difluoride membrane. Proteins were detected with the primary antibodies described above and horseradish peroxidase-conjugated anti-rabbit (AP307P, Chemicon International Inc., Temecula, CA, USA) or anti-mouse IgG (A-6782, Sigma-Aldrich, St Louis, MO, USA). The blots were incubated with SuperSignal West Pico ECL substrate and exposed to Kodak BioMax XAR or X-OMAT Blue XB-1 films. Densitometry analysis of the Western blots was performed using a Bio-Rad Fluor-S Multimager System (Bio-Rad Laboratories, Hercules, CA, USA).
For immunoprecipitation, cells were lysed in phosphatebuffered saline (PBS) supplemented with 1 mg/ml leupeptin, 0.2 mM PMSF and 0.1 TI U/ml aprotinin, and containing 0.5% Triton X-100, 0.1% sodium deoxycholate and 0.1% SDS. The undissolved debris was removed by centrifugation and the supernatants were precleared by incubation with protein A sepharose CL-4B beads (17-0780-01, Amersham Biosciences, Buckinghamshire, England, UK) or protein G sepharose 4B beads (p3296, Sigma-Aldrich, St Louis, MO, USA). Affinitypurified primary antibody against RUNX1, ETO, or HSP90 was added to the supernatant at a concentration of 2.0 mg/ml and incubated for 4 h to overnight at 41C. The normal rabbit IgG (sc-2027, Santa Cruz Biotechnology, Santa Cruz, CA, USA) or normal mouse IgG (sc-2025, Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used at same concentration as a negative control. A 60 ml aliquot of 50% slurry of abovementioned protein A or protein G beads was then added for 2 h to collect the immune complexes and these complexes were washed three times at 41C with lysis buffer. The bound proteins were eluted from the beads at 801C for 10 min in protein sample buffer containing 2% SDS and 0.5% 2-mercaptoethanol. Immunoblot analysis was performed using the antibodies indicated in the figures.
Cell cycle and apoptosis analysis
Kasumi-1 cells treated with DEP or DMSO were washed twice with ice cold PBS and fixed in 75% ethanol at À201C overnight. The cells were collected and resuspended in PBS at a concentration of 6 Â 10 5 /ml to 1 Â 10 6 /ml. The cells were filtered through nylon mesh, collected by centrifugation and resuspended in the same volume of PBS containing 0.1% Triton-X 100, 200 mg/ml RNase A, 10 mg/ml PI and 1% FBS. The cells were stained at 41C overnight. Flow cytometry analysis of DNA content was performed on a Becton Dickinson FACScalibur System (Becton Dickinson & Co., Franklin Lakes, NJ, USA). ModFit LT software (Version 3.1, Verity Software House Inc., Topsham, ME, USA) was used for subsequent analysis. Annexin V detection was performed using APC-conjugated Annexin V (BD Biosciences, San Jose, CA, USA), and apoptosis was blocked using 50 mM Z-VAD (BD Biosciences, San Jose, CA, USA), which was added to the culture medium 1 h before the addition of DEP.
